Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biological process and therefore defined as “biologics” has been successfully used in the treatment of immunemediated rheumatic diseases. These drugs target different pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small uncontrolled trials, with general and unexpected efficacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheumatic diseases. We used PubMed search engine as the main source of information. Among the papers included in the reference list, a particular emphasis was given on articles published during the last 5 years.
KeywordsBiologicsUveitis
Durrani, O.M., Meads, C.A. and Murray, P.I. (2004) Uveitis: A potentially blinding disease. Ophthalmologica, 21, 8223-8236.
Szekanecz, Z., Szanto, S., Szabo, Z., Vancsa, A., Szamosi, S., Bodnar, N., et al. (2010) Biologics-beyond the joints. Autoimmunity Reviews, 9, 820-824. doi:10.1016/j.autrev.2010.07.011
Bell, G.M., Reynolds, G. and Isaacs, J.D. (2011) Biologic therapies in non-rheumatic diseases: Lessons for rheumatologists? Nature Reviews Rheumatology, 7, 507-516. doi:10.1038/nrrheum.2011.106
Hyrich, K.L., Watson, K.D., Isenberg, D.A. and Symmons, D.P. (2008) The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford), 47, 1441-1443. doi:10.1093/rheumatology/ken242
Kahn, P., Weiss, M., Imundo, L.F. and Levy, D.M. (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology, 113, 860-864.
Emi Aikawa, N., de Carvalho, J.F., Artur Almeida Silva, C. and Bonfa, E. (2010) Immunogenicity of Anti-TNFalpha agents in autoimmune diseases. Clinical Reviews in Allergy & Immunology, 38, 82-89. doi:10.1007/s12016-009-8140-3
Aaltonen, K.J., Virkki, L.M., Malmivaara, A., Konttinen, Y.T., Nordstrom, D.C. and Blom, M. (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One, 7, e30275. doi:10.1371/journal.pone.0030275
Smith, J.R., Levinson, R.D., Holland, G.N., Jabs, D.A., Robinson, M.R., Whitcup, S.M., et al. (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis & Rheumatism, 45, 252-257. doi:10.1002/1529-0131(200106)45:3 3.0.CO, 2-5
Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., Kaklamanis, P. and Markomichelakis, N.N. (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet, 358, 295-296. doi:10.1016/S0140-6736(01)05497-6
Accorinti, M., Pirraglia, M.P., Paroli, M.P., Priori, R., Conti, F. and Pivetti-Pezzi, P. (2007) Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Japanese Journal of Ophthalmology, 51, 191-196. doi:10.1007/s10384-006-0425-y
Tugal-Tutkun, I., Mudun, A., Urgancioglu, M., Kamali, S., Kasapoglu, E., Inanc, M., et al. (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: An openlabel trial. Arthritis & Rheumatism, 52, 2478-2484. doi:10.1002/art.21231
Russell, A.I., Lawson, W.A. and Haskard, D.O. (2001) Potential new therapeutic options in Behcet’s syndrome. BioDrugs, 15, 25-35. doi:10.2165/00063030-200115010-00003
Pato, E., Munoz-Fernandez, S., Francisco, F., Abad, M.A., Maese, J., Ortiz, A., et al. (2011) Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Seminars in Arthritis and Rheumatism, 40, 314-323. doi:10.1016/j.semarthrit.2010.05.008
Evereklioglu, C. (2011) Ocular Behcet disease: current therapeutic approaches. Current Opinion in Ophthalmology, 22, 508-516. doi:10.1097/ICU.0b013e32834bbe91
Handa, T., Tsunekawa, H., Yoneda, M., Watanabe, D., Mukai, T., Yamamura, M., et al. (2011) Long-term remission of ocular and extraocular manifestations in Behcet’s disease using infliximab. Clinical and Experimental Rheumatology, 29, S58-63.
Keino, H., Watanabe, T., Taki, W. and Okada, A.A. (2011) Effect of infliximab on gene expression profiling in Behcet’s disease. Investigative Ophthalmology & Visual Science, 52, 7681-7686. doi:10.1167/iovs.11-7999
Keino, H., Okada, A.A., Watanabe, T. and Taki, W. (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. British Journal of Ophthalmology, 95, 1245-1250. doi:10.1136/bjo.2010.194464
Okada, A.A., Goto, H., Ohno, S. and Mochizuki, M. (2012) Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Archives of Ophthalmology, 130, 592-598. doi:10.1001/archophthalmol.2011.2698
Cantini, F., Niccoli, L., Nannini, C., Kaloudi, O., Cassara, E., Susini, M., et al. (2012) Efficacy of infliximab in refractory Behcet’s disease-associated and idiopathic posterior segment uveitis: A prospective, follow-up study of 50 patients. Biologics, 6, 5-12.
Ito, T., Sonoda, K.H., Hijioka, K., Fujimoto, T. and Ishibashi, T. (2010) Acquired resistance to infliximab against uveitis due to Behcet’s disease after one year of administration. Japanese Journal of Ophthalmology, 54, 502-504. doi:10.1007/s10384-010-0859-0
Suhler, E.B., Smith, J.R., Wertheim, M.S., Lauer, A.K., Kurz, D.E., Pickard, T.D., et al. (2005) A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Archives of Ophthalmology, 123, 903-912. doi:10.1001/archopht.123.7.903
Benitah, N.R., Sobrin, L. and Papaliodis, G.N. (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease. Seminars in Ophthalmology, 26, 295-303. doi:10.3109/08820538.2011.588665
Fries, W., Giofre, M.R., Catanoso, M. and Lo Gullo, R. (2002) Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. The American Journal of Gastroenterology, 97, 499-500. doi:10.1111/j.1572-0241.2002.05514.x
Ally, M.R., Veerappan, G.R. and Koff, J.M. (2008) Treatment of recurrent Crohn’s uveitis with infliximab. The American Journal of Gastroenterology, 103, 2150-2151. doi:10.1111/j.1572-0241.2008.01982_12.x
Kruithof, E., Kestelyn, P., Elewaut, C., Elewaut, D., Van Den Bosch, F., Mielants, H., et al. (2002) Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Annals of the Rheumatic Diseases, 61, 470. doi:10.1136/ard.61.5.470
Baraliakos, X., van den Berg, R., Braun, J. and van der Heijde, D. (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford), 51, 1378-1387. doi:10.1093/rheumatology/kes026
El Maghraoui, A. (2011) Extra-articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications. European Journal of Internal Medicine, 22, 554-560. doi:10.1016/j.ejim.2011.06.006
Mangge, H., Heinzl, B., Grubbauer, H.M., El-Shabrawi, Y. and Schauenstein, K. (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatology International, 23, 258-261. doi:10.1007/s00296-003-0308-1
Sharma, S.M., Ramanan, A.V., Riley, P. and Dick, A.D. (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: Efficacy in joint and ocular disease. Annals of the Rheumatic Diseases, 66, 840-841. doi:10.1136/ard.2006.065441
Khalifa, Y.M., Bailony, M.R. and Acharya, N.R. (2010) Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocular Immunology and Inflammation, 18, 218-222. doi:10.3109/09273941003739910
Sukumaran, S., Marzan, K., Shaham, B. and Reiff, A. (2012) High dose infliximab in the treatment of refractory uveitis: Does dose matter? ISRN Rheumatology, 2012, 765380.
Farvardin, M., Afarid, M. and Shahrzad, S. (2012) Longterm effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. Journal of Ocular Pharmacology and Therapeutics, 28, 628-631. doi:10.1089/jop.2011.0199
Markomichelakis, N., Delicha, E., Masselos, S. and Sfikakis, P.P. (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in behcet disease: A pilot study in 15 patients. American Journal of Ophthalmology, 154, 534-541. e1. doi:10.1016/j.ajo.2012.03.035
Rudwaleit, M., Rodevand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., et al. (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Annals of the Rheumatic Diseases, 68, 696-701. doi:10.1136/ard.2008.092585
Mushtaq, B., Saeed, T., Situnayake, R.D. and Murray, P.I. (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond), 21, 824-825. doi:10.1038/sj.eye.6702352
Takase, K., Ohno, S., Ideguchi, H., Uchio, E., Takeno, M. and Ishigatsubo, Y. (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatology International, 31, 243-245. doi:10.1007/s00296-009-1178-y
Kotaniemi, K., Saila, H. and Kautiainen, H. (2011) Longterm efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clinical Ophthalmology, 5, 1425-1429. doi:10.2147/OPTH.S23646
Erckens, R.J., Mostard, R.L., Wijnen, P.A., Schouten, J.S. and Drent, M. (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 713-720. doi:10.1007/s00417-011-1844-0
Diaz-Llopis, M., Salom, D., Garcia-de-Vicuna, C., Cordero-Coma, M., Ortega, G., Ortego, N., et al. (2012) Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology, 119, 1575-1581.
Leccese, P., Latanza, L., D’Angelo, S., Padula, A. and Olivieri, I. (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet’s disease to infliximab. Clinical and Experimental Rheumatology, 29, S93.
Bawazeer, A., Raffa, L.H. and Nizamuddin, S.H. (2010) Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocular Immunology and Inflammation, 18, 226-232. doi:10.3109/09273948.2010.483314
Dhingra, N., Morgan, J. and Dick, A.D. (2009) Switching biologic agents for uveitis. Eye, 23, 1868-1870. doi:10.1038/eye.2009.203
Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., et al. (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis & Rheumatism, 44, 1411-1415. doi:10.1002/1529-0131(200106)44:6 3.0.CO, 2-O
Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., et al. (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis & Rheumatism, 48, 1093-1101. doi:10.1002/art.10885
Reddy, A.R. and Backhouse, O.C. (2003) Does etanercept induce uveitis? British Journal of Ophthalmology, 87, 925. doi:10.1136/bjo.87.7.925
Reiff, A. (2003) Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis & Rheumatism, 48, 2079-2080. doi:10.1002/art.11155
Schmeling, H. and Horneff, G. (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology, 44, 1008-1011. doi:10.1093/rheumatology/keh658
Taban, M., Dupps, W.J., Mandell, B. and Perez, V.L. (2006) Etanercept (enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocular Immunology and Inflammation, 14, 145-150. doi:10.1080/09273940600659393
Lim, L.L., Fraunfelder, F.W. and Rosenbaum, J.T. (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis & Rheumatism, 56, 3248-3252. doi:10.1002/art.22918
Gaujoux-Viala, C., Giampietro, C., Gaujoux, T., Ea, H.K., Prati, C., Orcel, P., et al. (2012) Scleritis: A paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. The Journal of Rheumatology, 39, 233-239. doi:10.3899/jrheum.110865
Schafer, V.S. and Zwerina, J. (2012) Biologic treatment of large-vessel vasculitides. Current Opinion in Rheumatology, 24, 31-37. doi:10.1097/BOR.0b013e32834dc392
Muselier, A., Bielefeld, P., Bidot, S., Vinit, J., Besancenot, J.F. and Bron, A. (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocular Immunology and Inflammation, 19, 382-383. doi:10.3109/09273948.2011.606593
Shapiro, L.S., Farrell, J. and Haghighi, A.B. (2012) Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clinical Neurology and Neurosurgery, 114, 297-298. doi:10.1016/j.clineuro.2011.10.024
Tappeiner, C., Heinz, C., Ganser, G. and Heiligenhaus, A. (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? The Journal of Rheumatology, 39, 1294-1295. doi:10.3899/jrheum.120010
William, M., Faez, S., Papaliodis, G.N. and Lobo, A.M. (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of Ophthalmic Inflammation and Infection, 2, 231-233.
Planck, S.R., Woods, A., Clowers, J.S., Nicklin, M.J., Rosenbaum, J.T. and Rosenzweig, H.L. (2012) Impact of IL-1 signalling on experimental uveitis and arthritis. Annals of the Rheumatic Diseases, 71, 753-760. doi:10.1136/annrheumdis-2011-200556
Teoh, S.C., Sharma, S., Hogan, A., Lee, R., Ramanan, A.V. and Dick, A.D. (2007) Tailoring biological treatment: Anakinra treatment of posterior uveitis associated with the CINCA syndrome. British Journal of Ophthalmology, 91, 263-264.
Gul, A., Tugal-Tutkun, I., Dinarello, C.A., Reznikov, L., Esen, B.A., Mirza, A., et al. (2012) Interleukin-1betaregulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: An open-label pilot study. Annals of the Rheumatic Diseases, 71, 563-566. doi:10.1136/annrheumdis-2011-155143
Smith, K.G., Jones, R.B., Burns, S.M. and Jayne, D.R. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis & Rheumatism, 54, 2970-2982. doi:10.1002/art.22046
Meijer, J.M., Pijpe, J., Vissink, A., Kallenberg, C.G. and Bootsma, H. (2009) Treatment of primary Sjogren syndrome with rituximab: Extended follow-up, safety and efficacy of retreatment. Annals of the Rheumatic Diseases, 68, 284-285. doi:10.1136/ard.2008.092601
Smith, R.M., Jones, R.B., Guerry, M.J., Laurino, S., Catapano, F., Chaudhry, A., et al. (2012) Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis & Rheumatism, 64, 3760-3769. doi:10.1002/art.34583
Nakken, B., Munthe, L.A., Konttinen, Y.T., Sandberg, A.K., Szekanecz, Z., Alex, P., et al. (2011) B-cells and their targeting in rheumatoid arthritis—Current concepts and future perspectives. Autoimmunity Reviews, 11, 28-34. doi:10.1016/j.autrev.2011.06.010
Tappeiner, C., Heinz, C., Specker, C. and Heiligenhaus, A. (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Research, 39, 184-186. doi:10.1159/000103239
Davatchi, F., Shams, H., Rezaipoor, M., Sadeghi-Abdollahi, B., Shahram, F., Nadji, A., et al. (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). International Journal of Rheumatic Diseases, 13, 246-252. doi:10.1111/j.1756-185X.2010.01546.x
Heiligenhaus, A., Miserocchi, E., Heinz, C., Gerloni, V. and Kotaniemi, K. (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology, 50, 1390-1394. doi:10.1093/rheumatology/ker107
Miserocchi, E. and Modorati, G. (2012) Rituximab for noninfectious uveitis. Developments in Ophthalmology, 51, 98-109. doi:10.1159/000336188
Zulian, F., Balzarin, M., Falcini, F., Martini, G., Alessio, M., Cimaz, R., et al. (2010) Abatacept for severe antitumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care & Research, 62, 821-825. doi:10.1002/acr.20115